Véronique Blanchard

Title: Innovations of Véronique Blanchard in Neurodegenerative Research

Introduction

Véronique Blanchard is a prominent inventor based in Paris, France. She has made significant contributions to the field of neurodegenerative research, particularly through her innovative work on RNA interference (RNAi) technologies. Her research focuses on developing therapeutic strategies for treating synucleinopathies, which are a group of neurodegenerative disorders.

Latest Patents

Véronique Blanchard holds a patent for her invention titled "Variant RNAi against alpha-synuclein." This patent includes RNAi molecules designed to treat neurodegenerative synucleinopathies. The RNAi molecules specifically target the expression of alpha-synuclein (SNCA). Additionally, her patent encompasses expression constructs, vectors such as rAAV, cells, viral particles, and pharmaceutical compositions that utilize the RNAi technology. The methods and kits related to this RNAi are aimed at treating conditions such as Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.

Career Highlights

Véronique is associated with Genzyme Corporation, where she continues to advance her research in neurodegenerative diseases. Her work has garnered attention for its potential to provide new treatment options for patients suffering from these debilitating conditions.

Collaborations

Some of her notable coworkers include Bradford Elmer and Brenda Richards, who contribute to her research efforts and innovations in the field.

Conclusion

Véronique Blanchard's contributions to neurodegenerative research through her patented RNAi technology highlight her role as an influential inventor. Her work has the potential to significantly impact the treatment of various neurodegenerative disorders.